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Abstract: Platelet function testing is essential for the diagnosis of hemostasis disorders. While there
are many methods used to test platelet function for research purposes, standardization is often
lacking, limiting their use in clinical practice. Light transmission aggregometry has been the gold
standard for over 60 years, with inherent challenges of working with live dynamic cells in specialized
laboratories with independent protocols. In recent years, standardization efforts have brought
forward fully automated systems that could lead to more widespread use. Additionally, new technical
approaches appear promising for the future of specialized hematology laboratories. This review
presents developments in platelet function testing for clinical applications.
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1. Introduction
Over the last century, platelet function testing has undergone several transformations. From the
development of the Duke–Ivy bleeding time [1], to the invention of the light transmission aggregometer
by Gus Born [2], to the newer high throughput advances in platelet function testing [3,4], capturing
platelets in their natural ability to form aggregates in response to vascular injury remains a challenge.
This article presents recent developments in platelet function testing, and while it is difficult to
predict which approaches will translate into widespread clinical hematology laboratory use, aspects of
standardization, automation, and point-of-care devices will be specifically highlighted.
2. International Guidelines for Light Transmission Aggregometry Standardization
The invention of the now gold-standard light transmission aggregometer has rapidly
revolutionized platelet function testing. The seminal papers by Gus Born in the 1960s describe
this invention in the simplest terms [2,5–7], and while the technology has seen improvements in
bench footprint and user-friendliness over the years, the underlying methodology has remained
largely unchanged. The standard in the identification and diagnosis of primary hemostatic defects,
light transmission aggregometry (LTA) continues to be time-, labour- and blood sample-intensive,
rendering its use limited to specialized hematology laboratories. Even so, international surveys have
regularly highlighted a lack of standardization in laboratory practices, making the results difficult
to extrapolate to other centers [8–10]. Indeed, the Platelet Physiology Scientific and Standardization
Committee of the International Society on Thrombosis and Haemostasis has conducted the largest
global survey on LTA practices [8], including 359 laboratories from 48 countries. In this survey, the
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methodology of blood collection, processing and analysis were observed in each center. The results
of their report clearly demonstrate the need for methodological standardization among the different
centers worldwide. In order to overcome this issue, the International Society on Thrombosis and
Haemostasis has published an expert consensus for LTA standardization. This guidance includes
several statements on pre-clinical variables to be considered and recommendation for blood collection,
preparation of the platelet-rich plasma sample and the choice of platelet agonists for testing [10].
While this publication provides recommendations about technical procedures, Hayward et al. have
developed a consensus guide on how to interpret LTA results [9]. Finally, the British Committee for
Standards in Haematology has also published a guide about clinical investigation of heritable platelet
function disorders [11]. Altogether, these three guidelines bring important standardization of the
methodology and the interpretation of light transmission aggregometry testing, but in the absence of
international standard reagents, or a quality assessment program for LTA, standardization between
laboratories remains a challenge. Table 1 illustrates the differences in the recommended concentrations
of activators and ristocetin for LTA in international guidelines [9–14].
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Gamma-thrombin 50–200 ng/mL X
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Can allow the TP receptor to be distinguished from TXA2 synthesis deficiencies 
If arachidonic acid aggregation is abnormal 
If γ thrombin is abnormal 
If abnormalities in the thrombin receptors, Receptors targets: Calcium mobilization and procoagulant 
function 
To check the correct functioning of the PKC pathway 
GPVI specific activator 
To diagnose CalDAG-GEFI deficiency 
Thrombin receptors but without clotting 
* If normal, then 0.5-0.7 mg/mL; if absent then 2 mg/mL 
3. Light Transmission Aggregometry Revisited 
Light transmission aggregometry remains the gold standard platelet function test for clinical 
diagnosis of platelet function disorders. This technique determines platelet aggregation percentage 
in platelet-rich plasma by measuring the increase in light transmission in response to the addition of 
a platelet agonist to the platelet suspension. Recently, two developments have simplified the 
experimental procedure and are worth noting. First, the automation of light transmission platelet 
aggregation using dedicated software on routine laboratory instruments (such as the Sysmex CS-2x00 
series, Norderstedt, Germany) introduces the possibility of running light transmission aggregometry 
without dedicated experienced personnel. The automated assay allows the user to select the agonists 
and their concentrations to be tested, in accordance with institutional, national, or international 
guidelines. The instrument then carries out automated light transmission aggregometry. In instances 
where it has been compared head-to-head with traditional light transmission aggregometry (Table 
2), the Sysmex CS-2000i has shown repeatability, reproducibility and agreement with traditional 
aggregometers [15–18]. While the technology is certainly advantageous in terms of labour 
requirement, it still calls for an appreciable volume of platelet-rich plasma (140 µL per test) albeit less 
than traditional aggregometry (200–500 µL per test) [16]. Notwithstanding, the automated acquisition 
allows for concentration-response curves to be generated more readily than with traditional 
aggregometry. While the gain in personnel time is undeniable, the time to run the assays has 
remained sensibly the same, and the cost of reagents and consumables is higher than that of 
traditional aggregometry. Interpretation continues to rely on expert examination of aggregation 
tracings from a patient, in comparison with tracings from a healthy control, by an experienced 
hematologist or clinical pharmacologist. However, it is foreseeable that the automated assay could 
be run in non-specialist centers, with the results sent to a tertiary center for interpretation. The 
standardization of the automated assay could also alleviate some of the issues around reproducibility 
among laboratories worldwide. 
The second development worth mentioning is that of high-throughput 96- to 384-well based 
platelet function assays, which allow a much broader overview of platelet function in significantly 
less time [3,4,19]. The plate-based assays offer the advantage of reduced platelet-rich plasma volume 
(50–100 µL per test for 96-well plates, 10 µL per test for 384-well plates) and time, as all assays are 
carried out simultaneously. Platelet function can be measured either kinetically or as an endpoint 
(e.g., after five minutes) and the results are converted into percentage of aggregation in a similar 
fashion to traditional light transmission aggregometry-based results. The large number of 
simultaneous aggregations that can be run on a plate make concentration–response curves to 
numerous agonists easy to generate, although these can be hard to interpret [20,21]. These assays 
remain restricted to research laboratories. Direct comparison of the 96-well plate assay with 
traditional light transmission aggregometry has revealed that the assays behave slightly differently 
in their sensitivity to agonists despite a similar methodological framework [22,23]. While these plate-
based assays could be used as a preliminary screening assay outside of specialized centers, they 
should not be regarded as a replacement for traditional aggregometry. 
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3. Light Transmission Aggregometry Revisited
Light transmission aggregometry remains the gold standard platelet function test for clinical
diagnosis of platelet function disorders. This technique determines platelet aggregation percentage in
platelet-rich plasma by measuring the increase in light transmission in response to the addition
of a platelet agonist to the platelet suspension. Recently, two developments have simplified
the experimental procedure and are worth noting. First, the automation of light transmission
platelet aggregation using dedicated software on routine laboratory instruments (such as the Sysmex
CS-2x00 series, Norderstedt, Germany) introduces the possibility of running light transmission
aggregometry without dedicated experienced personnel. The automated assay allows the user to
select the agonists and their concentrations to be tested, in accordance with institutional, national,
or international guidelines. The instrument then carries out automated light transmission aggregometry.
In instances where it has been compared head-to-head with traditional light transmission aggregometry
(Table 2), the Sysmex CS-2000i has shown repeatability, reproducibility and agreement with traditional
aggregometers [15–18]. While the technology is certainly advantageous in terms of labour requirement,
it still calls for an appreciable volume of platelet-rich plasma (140 µL per test) albeit less than traditional
aggregometry (200–500 µL per test) [16]. Notwithstanding, the automated acquisition allows for
concentration-response curves to be generated more readily than with traditional aggregometry. While
the gain in personnel time is undeniable, the time to run the assays has remained sensibly the same,
and the cost of reagents and consumables is higher than that of traditional aggregometry. Interpretation
continues to rely on expert examination of aggregation tracings from a patient, in comparison with
tracings from a healthy control, by an experienced hematologist or clinical pharmacologist. However,
it is foreseeable that the automated assay could be run in non-specialist centers, with the results sent to
a tertiary center for interpretation. The standardization of the automated assay could also alleviate
some of the issues around reproducibility among laboratories worldwide.
The second development worth mentioning is that of high-throughput 96- to 384-well based
platelet function assays, which allow a much broader overview of platelet function in significantly
less time [3,4,19]. The plate-based assays offer the advantage of reduced platelet-rich plasma volume
(50–100 µL per test for 96-well plates, 10 µL per test for 384-well plates) and time, as all assays are
carried out simultaneously. Platelet function can be measured either kinetically or as an endpoint
(e.g., after five minutes) and the results are converted into percentage of aggregation in a similar fashion
to traditional light transmission aggregometry-based results. The large number of simultaneous
aggregations that can be run on a plate make concentration–response curves to numerous agonists
easy to generate, although these can be hard to interpret [20,21]. These assays remain restricted to
research laboratories. Direct comparison of the 96-well plate assay with traditional light transmission
aggregometry has revealed that the assays behave slightly differently in their sensitivity to agonists
despite a similar methodological framework [22,23]. While these plate-based assays could be used
as a preliminary screening assay outside of specialized centers, they should not be regarded as a
replacement for traditional aggregometry.
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Table 2. Summary of studies comparing the automated light transmission aggregometers to traditional devices.
Study AssessedInstrument Reference Instrument Samples Agonists Results Comments on Assessed Instrument







ADP 5 µM, AA 500 µg/mL, Col
2.5 µg/mL, Epi 5.4 µM, Risto
1.5 mg/mL (Hyphen Biomed)
Strong correlation between both
instruments (Pearson’s r: 0.69 to 0.88)
Good repeatability of CS-2100i (MA
CV < 10%)
Inhibitory effect of PPP on
aggregation induced by ADP, AA,
Col, Epi
Inhibitory effect of PS on
ristocetin-induced aggregation
Short turnaround time
Low PC requirement in PRP:
80 × 109/L





subjects or patients on
NSAID (n = 14) or
clopidogrel (n = 2)
ADP 0.5–10 µM, AA 0.12–1.0
mM
Col 0.5–10 µg/mL, Epi
0.5–10 µM, Risto 0.75–1.25
mg/mL (Hyphen Biomed)
Comparable dose-responses with each of
the agonists with both instruments
Comparable aggregation traces with
samples from subjects under NSAID or
clopidogrel
Similar aggregation imprecision (MA and
slope CV to ADP: 3–12%)
Influence of cuvette stirrer speed on
the reaction sensitivity: optimum
speed of 800 rpm
No clinically significant changes in
aggregation response for PC ranging
from 150–480 × 109/L in PRP, but
poor sensitivity in case of PC
<100 × 109/L






(n = 46) or with ACS
(n = 62) receiving dual
antiplatelet therapy
ADP 2.5–10 µM, AA 0.5
mg/mL, Col 3.3 µg/mL, Epi
10 µM, Risto1.25 mg/mL
(Hyphen Biomed)
Significant correlations between both
instruments (Pearson’s r: 0.38 to 0.98)
Similar aggregation profiles with both
systems in patients with bleedings
(including 1 GT patient)
Strong inter-agreement rates to detect low
responders to thienopyridines or aspirin
(weighted kappa> 0.70)
Good intra-serial imprecision of CS-2000i
(MA CV < 5% for each agonist)
Cuvette stirrer speed: 800 rpm







therapy (n = 49)
ADP 0.5–10 µM, AA 1 mM, Col
2 µg/mL, Risto 0.625 and 1.2
mg/mL (Hyphen Biomed)
Significant correlation between the two
aggregometers (Passing and Bablok’s r: 0.48
to 0.90)
More variable response using low
concentrations of ADP (≤5 µM) with
Sysmex CS-2500
Discrepancies with the low dose of
ristocetin: excessive paradoxical
agglutination with the Sysmex CS-2500
Good intra-serial imprecision of CS-2500
(MA CV to ADP: 1.5%)
Cuvette stirrer speed: 600 rpm
AA: arachidonic acid, ACS: acute coronary syndrome, ADP: adenosine diphosphate, Col: collagen, CV: coefficient of variation, Epi: epinephrine, GT: Glanzmann thrombasthenia, MA:
maximum aggregation, NSAID: nonsteroidal anti-inflammatory drugs (i.e., aspirin or ibuprofen), PC: platelet count, PFD: platelet function disorder, PPP: platelet poor plasma, PRP:
platelet rich plasma, PS: physiological saline, Risto: ristocetin, vWD: von Willebrand Disease.
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Table 2. Cont.
Study AssessedInstrument Reference Instrument Samples Agonists Results Comments on Assessed Instrument





subjects (n = 61) and
from patients with
known bleeding
disorder (n = 20) or
antiplatelet therapy
(n = 42)
ADP 5 µM, AA 1 mM, Risto 1
mg/mL), Col 2 µg/mL, Epi
5 µM (Hyphen Biomed)
Significant MA correlation between both
instruments with all subgroups and agonists
tested (Pearson’s r ≥ 0.85)
Weak or no correlation between both
instruments in regard to lag time (Pearson’s
r < 0.20)
Systematic bias to lower measurements
below a threshold of 50% MA with the
CS-2100i
Successful identification of patients with
known bleeding disorder or antiplatelet
therapy using the CS-2100i
Non-adjusted PRP
Reading period of 600 s
AA: arachidonic acid, ACS: acute coronary syndrome, ADP: adenosine diphosphate, Col: collagen, CV: coefficient of variation, Epi: epinephrine, GT: Glanzmann thrombasthenia, MA:
maximum aggregation, NSAID: nonsteroidal anti-inflammatory drugs (i.e., aspirin or ibuprofen), PC: platelet count, PFD: platelet function disorder, PPP: platelet poor plasma, PRP:
platelet rich plasma, PS: physiological saline, Risto: ristocetin, vWD: von Willebrand Disease.
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4. Evaluation of Granule Defects
There is evidence that dense granule secretion defects can be misdiagnosed if relying
solely on platelet aggregometry [25,26]. A modified version of light transmission aggregometry,
the lumi-aggregometer, provides information on platelet secretion in parallel with platelet aggregation
measures [25]. In this method, the ATP secreted by platelets is quantified using a luciferin/luciferase
assay, while aggregation data is collected as in classical LTA. The combined analysis of platelet
aggregation and secretion function by lumi-aggregometry enhances the detection of platelet disorders
affecting dense granule release [27].
Several instruments are available to measure lumi-aggregometry (Chronolog series). However,
there are few reports available in the literature on the validation and the performance of
lumi-aggregometry. Lumi-aggregometry is affected by several variables including: concentration
of luciferin/luciferase, concentration of agonists, volume of PPP and PRP, concentration of ATP
standard, duration of incubation, duration of measurement and adjustment of platelet count of the
PRP. As for LTA, non-parametric analyses are the preferred method to establish reference intervals
for lumi-aggregometry [9,28,29]. Lumi-aggregometry estimates of platelet dense granule ATP release
have a considerably higher CV (around 20–30%) than LTA. A recent report on 150 unique subjects
who had multiple ATP release tests has shown that normal findings with all tested agonists were often
confirmed by the second test, but impaired release with multiple agonists was confirmed in only some
subjects. Inconsistent findings were thus common. The finding of impaired ATP release with two or
more agonists on both tests was not associated with an increased likelihood of a definite bleeding
disorder [30]. The variability in platelet dense granule ATP release findings amongst patients assessed
for diagnostic purposes suggests that the test has limited value for diagnosing platelet disorders.
However, these results should be confirmed by other groups before drawing firm conclusions.
In addition, caution should be used in patients with Quebec Platelet Disorder when assessing
ATP secretion with the use of the Chronolume® commercial reagent (containing 0.2 mg luciferin,
22,000 units d-luciferase plus magnesium sulphate, human serum albumin, stabilizers and buffer).
Indeed, Hayward et al. found that addition of Chronolume® consistently induced a secondary wave
of aggregation in response to epinephrine in platelets obtained from patients with Quebec Platelet
Disorder, whereas assessment of aggregation without Chronolume® showed the expected absence of a
secondary wave consistent with the pathology [31]. This finding however appeared to be restricted
to patients with Quebec platelet disorder, as other investigators have reported no adverse effect of
Chronolume® addition in investigating platelet disorders [32,33]. These findings come from relatively
small cohorts, and there remains an unmet need for systematic evaluation and standardization of
methodologies for clinical laboratories using lumi-aggregometry.
A limitation of platelet lumi-aggregometry is that it does not distinguish between dense granule
deficiency and primary secretion defects that may also rely on defects in signaling pathways. Therefore,
assessment of the endogenous content of dense granules alongside lumi-aggregometry is important [11].
For that purpose, several strategies have been proposed, such as the measurement of platelet serotonin or
nucleotides levels, using liquid chromatography, mass spectroscopy, immunoassays or flow cytometry.
However, whole-mount transmission electron microscopy (TEM), which allows the direct quantification
of platelet dense granules due to their calcium content, remains the gold standard and has been the
subject of recent standardization efforts [34]. Despite being less accessible than LTA or ATP release
assays in routine testing, this technology appears to be more sensitive and reproducible for detecting
dense granule deficiencies associated with a bleeding tendency [35]. Beyond simply counting the
number of dense granules per platelet, the measurement of their diameter could also be of importance
in TEM as nearly 30% of bleeding patients with a normal number of dense granules may have smaller
granules, leading to a reduced storage pool volume [36]. The study of platelet ultrastructure in
TEM, although more complex to implement, is also very useful for the characterization of various
platelet defects associated with the cytoskeleton and granule abnormalities, such as gray platelet
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syndrome, Paris-Trousseau syndrome, storage pool diseases, MYH9-related thrombocytopenia, or
Wiskott–Aldrich syndrome, but is reserved to highly specialized laboratories [37].
Also of importance, while lumi-aggregometry assesses dense granule secretion, it fails to address
secretion from α-granules, lacking a chromo-genic component [38]. In addition to TEM methods that
allow assessment of α-granule number and morphology, immunofluorescence assays on blood smears
are emerging as promising tools to characterize platelet α-granules [39]. Fluorescence microscopy
on blood smears has been proposed to facilitate the diagnosis of several inherited platelet disorders
associated with changes in platelet proteins, such as Glanzmann thrombasthenia, Bernard Soulier
disease, and delta storage pool deficiencies, or macrothrombocytopenia associated with filamin A,
GFI1B and β1-tubuline anomalies, for example [40]. Based on the preparation of standard peripheral
blood smears followed by immunofluorescence labeling of various platelet components, this approach
may be of interest in non-specialized centers worldwide (that may ship blood smears by regular mail
to a specialized center), and particularly in pediatric population since it requires very low volumes of
blood (<100 µL).
Genetic screening has also become an integral part of evaluating a patient presenting with inherited
bleeding and platelet disorders [41,42], and has identified a number of important transcription factors
involved in granule biogenesis and maturation that lead to bleeding disorders. Although informative,
genetic screening cannot be taken in isolation, as the phenotype or functional readout of genetic
findings is hard to predict. Characterization of α-granule contents by simple (ELISA) or multiple
(e.g., Luminex® or bead-based flow cytometry) immunological assays, can offer insights into the ability
of platelets to secrete key vasoactive peptides in response to activation [27]. A frequently-used marker
of α-granule fusion with the plasma membrane, flow cytometric assessment of P-selectin (CD62p)
levels on platelets before and after activation with platelet agonists, may also indicate defects in
α-granule biology. Although there is growing international expertise in assessing platelet α-granules,
there are so far no universally accepted standardized assays that have been recommended in clinical
practice [27].
5. Multiple Electrode Aggregometry
The impedance aggregometer has been described for the first time in 1980 [43]. In this technique,
platelet aggregation is assessed by the change of electrical impedance in whole blood or in platelet-rich
plasma, between two electrodes. Following agonist stimulation, platelets aggregate to the electrodes,
impairing the conduction of electrical current between them. The development of a semi-automated
system (Multiplate®, Roche Diagnostics) has allowed wide uptake of these instruments in hematology
laboratories, especially for P2Y12 inhibitor monitoring [44]. Multiplate® may be used to assess risk of
bleeding or thrombosis during prolonged dual antiplatelet therapy and to shorten the time window to
surgery following P2Y12 inhibitor discontinuation [45–47]. There is evidence, albeit limited, to support
the use of impedance aggregometry for the diagnosis of severe platelet function disorders [48–50].
However, multiple electrode aggregometry was shown to be inferior to LTA for the detection and
discrimination of mild platelet function disorders [49,51–53], since it provides no information about
platelet shape change and the reversibility of aggregation. As such, its use is not recommended as
a screening test for the diagnosis of bleeding disorders. Finally, several preanalytical and analytical
variables affect the results provided by the instrument, including time-interval since blood drawing
and analysis, type of anticoagulant, and platelet count [54,55].
6. Detection of Platelet Activation Markers by Flow Cytometry
Flow cytometry is another popular technique for platelet phenotyping. In contrast to aggregometry
methods that study dynamic platelet aggregation, flow cytometry can shed insight on the platelet
activation status, through analysis of the expression of activation markers. Two studies have compared
light transmission aggregometry, with the measure of the expression of P-selectin and activated
GPIIbIIIa on the platelet surface by flow cytometry in the detection of inherited platelet disorders [56,57].
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The results highlight that flow cytometry has the advantage of requiring a smaller volume of blood
and to not require platelet-rich plasma preparation. With a negative predictive value of 87%, flow
cytometry analysis has the potential to be used as a screening test to perform before light transmission
aggregometry. Thus, both studies have concluded that this technique provides complementary
information for platelet function defects, even though further validation and standardization tests are
required before use in diagnostic laboratories. In this respect, the setting of an appropriate threshold
when studying platelet activation, the use of mean/median fluorescence intensity levels vs. % of positive
platelets for a certain biomarker, the nature and concentration of agonists used to induce platelet
activation, the use of fixatives (either before or after platelet staining) can all influence interpretation of
flow cytometry-based platelet assessments and require standardization [58].
Another potential useful flow cytometry assay is the mepacrine assay which permits an evaluation
of the incorporation and secretion capacities of platelets. The mepacrine captured by the δ-granules
is then secreted upon stimulation of the cells with various agonists. Platelet fluorescence can thus
be quantified by flow cytometry before and after stimulation. Mepacrine assays may be used to
exclude platelet dense granule deficiency [59,60]. However, the mepacrine assay is also affected by
a lack of standardization. Some of the variables include mepacrine concentration, temperature of
mepacrine incubation, concentration and type of agonist used to stimulate platelets and mode of result
expression. Alternatively, δ-granules secretion may be assessed by measuring the expression of CD63,
a protein naturally present in the membrane of lysosomes and δ-granules, and which is translocated
on the platelet surface upon platelet activation [61]. As well as lumi-aggregometry, this approach does
not differentiate between storage pool deficiency and primary secretion defects, and its combination
with mepacrine has been proposed to better characterize dense granules disorders [60]. Finally, flow
cytometry is also used to detect the expression of phosphatidylserine on activated platelets in the case
of a suspected diagnosis of Scott syndrome [62].
7. Microfluidics and Microscopy
Understanding platelet function as it occurs within a vessel requires elements of flow to be taken
into account. Several point-of-care assays have been developed over the years that incorporate an
element of shear, including the PFA-100/200®, Impact®—the cone and platelet analyzer, and Placor®
PRT. Of these, only the PFA-200® remains clinically available, despite being fairly insensitive for the
detection of mild platelet function defects [11,63]. In research laboratories, parallel-plate flow chambers
have been in use since the 1970s and have allowed multiple discoveries to be made regarding the
behavior of platelets under physiological and pathological flow [4]. It is only recently that microfluidic
devices have been developed for clinical laboratory use. The principle of the assay is simple; it requires
blood to be flowed over a surface coated with a thrombogenic substrate (usually collagen) and the
assessment of platelet deposition and thrombus growth by microscopy. The Total Thrombus-formation
Analysis System (T-TAS 01®) is one such example in clinical laboratory use. It is a flow-microchip
chamber with thrombogenic surfaces that easily generates images for two-dimensional analysis of
area covered by thrombi, in an imitation of a vessel wall injury [64–69]. Similar to the closure time
reported by the PFA-200®, the T-TAS 01® instrument reports the flow pressure waveform as the platelet
plug obstructs blood flow through the microchip. Its dual-monitoring system adds real-time video
imaging (Figure 1), which allows visual assessment of the thrombus formed under variable blood flow
conditions. It has been successfully used for the diagnosis and characterization of von Willebrand
disease [65], as a screening test for platelet storage pool disease [67,70], for monitoring of antiplatelet
therapy [66,68,70], and for the prediction of periprocedural bleeding in patients undergoing coronary
artery bypass surgery [71].
J. Clin. Med. 2020, 9, 2636 11 of 18
J. Clin. Med. 2020, 9, x FOR PEER REVIEW 9 of 16 
 
 
Figure 1. Principle of the T-TAS® system for simplified evaluation of platelet plug formation in clinical 
laboratories. Reproduced with permission from Fujimori Kogyo, Co. Ltd, Tokyo, Japan. 
Several developments in the world of microfluidic devices are underway. A multi-modal 
approach with different coating proteins in addition to collagen appears promising to investigating 
platelet function under flow in clinical settings, including severe combined immune deficiency, 
Glanzmann thrombasthenia, Hermansky–Pudlak syndrome, MYH9-related disease, or grey platelet 
syndrome [72]. Microfluidic devices that incorporate endothelial cells could be useful in assessing 
platelet function in hematologic diseases such as sickle cell disease and hemolytic uremic syndrome 
[73]. These advances are yet to achieve sufficient standardization to reach the clinical laboratory, but 
they could dramatically change the way we assess platelet function in bleeding or thrombotic 
disorders. 
8. Platelet Function Testing in Thrombocytopenia 
It is not rare that low platelet counts hamper assessment of platelet function by traditional 
assays, as most platelet function tests are not reliable when platelet counts fall below the normal range 
[74]. Yet, previous research has shown that bleeding risk is not directly correlated with platelet count. 
For example, clinically significant bleeding occurred on 25% of days when platelet counts reached ≤ 
5 x 109/L, 17% of days when platelet counts varied between 6 and 80 × 109/L, 13% of days when platelet 
counts ranged from 81 to 100 × 109/L, and 8% of days with platelet counts ≥ 100 x 109/L, in a study of 
patients with hematological or oncological disorders [75]. This suggests that other qualitative factors 
may contribute to the risk of bleeding in addition to low platelet counts in patients with 
thrombocytopenia. 
Options for assessment of platelet function in patients with low and very low platelet counts 
rely on flow cytometric assays of platelet activation markers. In recent years, several flow cytometry 
approaches have been successfully used to assess platelet function in patients with severe chronic 
immune thrombocytopenia, showing that impaired platelet function is associated with bleeding, 
independent of platelet count [76–78]. However, it should also be noted that simply decreasing the 
platelet count induces an impaired platelet function phenotype as measured by flow cytometry, due 
to the loss of paracrine amplification of platelet responses by ADP release [79]. This indicates that 
flow cytometric assessment of platelet function is affected by platelet count, admittedly to a lesser 
extent than other traditional platelet function assays, and highlights the importance of deriving 
platelet-count-adjusted reference ranges. 
Figure 1. Principle of the T-TAS® system for simplified evaluation of platelet plug formation in clinical
laboratories. Reproduced with permission from Fujimori Kogyo, Co. Ltd, Tokyo, Japan.
Several developments in the world of microfluidic devices are underway. A multi-modal approach
with different coating proteins in addition to collagen appears promising to investigating platelet
function under flow in clinical settings, including severe combined immune deficiency, Glanzmann
thrombasthenia, Hermansky–Pudlak syndrome, MYH9-related disease, or grey platelet syndrome [72].
Microfluidic devices that incorporate endothelial cells could be useful in assessing platelet function in
hematologic diseases such as sickle cell disease and hemolytic uremic syndrome [73]. These advances
are yet to achieve sufficient standardization to reach the clinical laboratory, but they could dramatically
change the way we assess platelet function in bleeding or thrombotic disorders.
8. Platelet Function Testing in Thrombocytopenia
It is not rare that low platelet counts hamper assessment of platelet function by traditional assays,
as most platelet function tests are n t reliable when platelet counts fall below the normal range [74].
Yet, previous research has shown that bleeding risk is not directly correlated with platelet count.
For example, clinically significant bleeding occurred on 25% of days when platelet counts reached
≤ 5 × 109/L, 17% of days when platelet counts varied between 6 and 80 × 109/L, 13% of days when
platelet counts ranged from 81 to 100 × 109/L, and 8% of days with platelet counts ≥ 100 × 109/L,
in a study of patients with hematological or oncological disorders [75]. This suggests that other
qualitative factors may contribute to the risk of bleeding in addition to low platelet counts in patients
with thrombocytopenia.
Options for assessment of platelet function in patients with low and very low platelet counts
rely on flow cytometric assays of platelet activation markers. In recent years, several flow cytometry
approaches have been successfully used to assess platelet function in patients with severe chronic
immune thrombocytopenia, showing that impaired platelet function is associated with bleeding,
independent of platelet count [76–78]. However, it should also be noted that simply decreasing
the platelet count induces an impaired platelet function phenotype as measured by flow cytometry,
due to the loss of paracrine amplification of platelet responses by ADP release [79]. This indicates
that flow cytometric assessment of platelet function is affected by platelet count, admittedly to a
lesser extent than other traditional platelet function assays, and highlights the importance of deriving
platelet-count-adjusted reference ranges.
Among the available platelet function assays, flow cytometry remains the superior approach to
measure platelet function in thrombocytopenia, and several developments are underway to improve
on the technology. One such example is the use of multiplex flow cytometry to assess the signaling
pathways involved in platelet responses to multiple agonists [80]. Whether these high-throughput flow
cytometry approaches will allow for the better characterization of platelet function in thrombocytopenia
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remains to be established. However, the technology is ready for implementation in larger cohorts,
and possibly in patients with bleeding disorders.
9. Reference Ranges & Interpretation
An important part of a platelet function defect diagnosis remains establishing normal reference
ranges for each test. Thus, the North American consensus guideline for medical laboratories performing
LTA recommend to locally establish the normal range of the maximal aggregation percentage for
each concentration of the activators, with a minimum of 40 healthy control volunteers [9]. While this
recommendation compensates for technique variation between different medical centers, it is also
noteworthy that several characteristics of the patient himself influence the normal reference range
of platelet function testing results. Indeed, it is known that platelet count, structure and activity
vary during aging [81,82], and that platelet function slightly differs between genders [82–85] and
among different ethnic groups [85,86]. Other authors have also highlighted significant differences in
aggregation curves in platelets of neonates and pregnant women compared to those of adults in the
general population [87]. In an attempt to determine normal reference values in platelet function testing
with flow cytometry, a study has found that the inter-individual variation is approximately 23% for
P-selectin expression and 37% for αIIbβ3 activation [82], confirming the importance for the clinician to
consider the characteristics of the patient for the interpretation of platelet function tests results. Finally,
intra-individual day-to-day variation in platelet function are also observed, justifying the necessity to
repeat at least once a test with an abnormal result to confirm the diagnosis.
10. Genetic Screening of Patients with Inherited Platelet Disorders
Genetic analyses are increasingly used in patients with bleeding disorders if there are strong clinical
and biological arguments in favour of an inherited platelet function disorder [42]. The gene-target
approach, which consists of studying a given gene, has long been used to confirm the diagnosis of
various platelet function disorders associated with a typical biological and/or clinical phenotype,
such a Glanzmann thrombasthenia or syndromic disorders for example. However, inherited platelet
disorders are very heterogeneous, with more than 50 currently known genes [88], and in most cases,
a single candidate gene cannot be found despite sometimes extensive family histories. In recent
decades, next generation sequencing (NGS) has revolutionized the landscape of molecular diagnostics
by increasing throughput, providing an unbiased genetic screen, and identifying rare variants not
always accessible with other technologies [41]. Allowing much faster identification of known genetic
defects, but also discovery of new defects, NGS is promising for overcoming diagnostic wandering [88].
However, it still suffers from limitations, such as lack of accessibility, high cost, and sometimes
difficulties in assigning pathogenicity to novel identified variants, in addition to ethical debates around
its use [41,89]. Notwithstanding, future laboratory assessment of individuals with inherited platelet
function disorders will certainly rely on a mix of clinical, genetic, morphological, and functional
investigations, altogether harnessing a more exhaustive platelet characterization.
11. Conclusions
There are still many challenges to accurately capturing in vivo platelet function with in vitro
assays. Future assays will have to find a way to assess platelet interaction with the vessel wall,
a likely contributor to certain bleeding phenotypes, independent of platelet aggregation profiles.
The development of new platelet function assays is a high-risk endeavor, and not surprisingly,
many assays that are promising in research settings do not make it into the clinical laboratory.
Nevertheless, improvements in automation, standardization, and usability are likely to render platelet
function testing available outside of specialized hematology laboratories in the next few years.
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